From narrow volume windows to SGLT2 inhibitors and emerging devices, Drs Kevin Alexander and Sarah Cuddy discuss heart ...

"I was 405 pounds and in the hospital after a bout with COVID. I had diastolic heart failure and lung complications. One of ...

Poster will feature in vivo efficacy profile of one of Augustine’s HDAC6 inhibitor development candidatesLEUVEN, Belgium –2 June 2026 – Augustine ...

Sleep breathing disorders (SBDs)—including obstructive sleep apnoea, central sleep apnoea and sleep-related hypoventilation syndromes—represent a major yet under-recognised contributor to global ...

Prof Joseph Atiah Akamah, an Interventional Cardiologist and Cardiovascular Epidemiologist, has advised me to adhere to ...

Pemvidutide improves fibrosis markers, liver fat, lipids, weight, and blood pressure in patients with MASH at 1 year, phase ...

HAYA Therapeutics doses first cohort in phase 1 clinical trial of HTX-001 for cardiac fibrosis: Lausanne, Switzerland Friday, May 22, 2026, 15:00 Hrs [IST] HAYA Therapeutics SA, a ...

Tissue Dynamics Ltd. and Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on liver, cardiometabolic, and GI oncology diseases, ...

A 38-year-old company employee, Kim, recently received a diagnosis of ‘hypertension’ during a health checkup. His systolic ...

Key Points Interested in Cytokinetics, Incorporated? Here are five stocks we like better. MYKORZO's launch is outperforming expectations, with Cytokinetics saying early prescriptions, reimbursements, ...

Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that new 48-week data from the IMPACT Phase 2b ...

IT’S been touted by health gurus for years who claim it can combat cramps, bloating and even excess wind. But experts now believe that peppermint oil could even help slash high blood ...